Proposed Supportive Pulmonary Surfactant for the Treatment of COVID-19 Infection
Despite the several treatments and immunizations that have been suggested, none have been able to stop the spread of SARS-cov-2, which has been ongoing for more than two years.
In this study, we first advocate for the replacement of pulmonary surfactant (PS) in patients who have been hospitalized to intensive care. Acute Respiratory Distress Syndrome (ARDS) in premature neonates is frequently treated with pulmonary surfactant, and studies have shown that it is extremely successful. Because SARS-CoV-2 infection and ARDS, also known as hyaline membrane disease, have many pathogenetic and symptomatological characteristics, using pulmonary surfactant as a supplement to existing treatments may be advantageous. Using the surfactant we suggest in our work, even drugs with low absorption and bioavailability can be administered directly into the most obscure alveolar areas.
Representative Lipotech, 56022 Castelfranco di Sotto (PI), Via dei Lazzeri, 33, Italy.
Surgeon, general surgery specialist, freelancer, 53043 Chiusi (SI), Via Montegrappa 1, Italy.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Perugia, Italy.
Please see the link here: https://stm.bookpi.org/CPMS-V5/article/view/7659
Keywords: SARS-CoV-2, pulmonar surfactant, ARDS, PROSURF